65 results
Primary Objective:To demonstrate pharmacokinetic biosimilarity of ONS-1045 (Oncobiologics) to the EU- and US licensed product of Avastin® following a single 2.0 mg/kg i.v. infusion, in healthy male adult subjects.Secondary objective:• To evaluate…
The main aim of this study is to find out if the continuation of bevacizumab, in addition to standard 2nd & 3rd -line treatment, can help patients with NSCLC that has progressed to live longer. The study also aims to find out if continued…
This study has two primary objectives:To determine the effect of taxane therapy on the release of bone marrow derived endothelial progenitor cells.To study the effect of bevacizumab on taxane induced release of bone marrow derived endothelial…
Primary objectivesTo establish the safety and tolerability of1. two doses of bevacizumab 7.5 mg/kg administered every 3 weeks with concurrent thoracic radiotherapy to 66 Gy;2. concurrent (7.5 mg/kg) and maintenance (15 mg/kg) bevacizumab during, and…
Primary objectivesDetermine the effect of Sorafenib (Bay 43-9006) on the uptake of In-111 labeled chimeric monoclonal antibody G250 (In-111-cG250) by RCC lesions.Determine the effect of Sorafenib (Bay 43-9006) on the uptake of In-111 labeled…
Primary Objective is to study the anti-tumor activity of the combination bevacizumab and metronomic dose temozolomide in patients with recurrent high grade gliomas. Secondary Objective is to investigate the effects of dexamethasone and bevacizumab…
Evaluation of the safety and tolerability of Bevacizumab added to standard induction chemotherapy. Evaluation of the effect of Bevacizumab on the CR rate
Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases
Evaluation of tumor localization of In-111 labeled bevacizumab and possible correlation with VEGF expression in patients with colorectal liver metastases.
To evaluate the efficacy, safety, tolerability, and pharmacokinetics of bevacizumab when added to postoperative radiotherapy with concomitant and adjuvant temozolomide (TMZ) and to determine whether the addition of anti-angiogenic therapy with…
To demonstrate that combined (repeated) laser photocoagulation prolongs time to failure compared to anti-VEGF monotherapy.
Assessment whether the addition of bevacizumab to lomustine improves overall survival in patients with recurrent glioblastoma
The goal of the trial is to compare the efficacy and costs of bevacizumab 1.25 mg and ranibizumab 0.5mg given as monthly intravitreal injections over 6 months for the treatment of macular edema secondary to a retinal vein occlusion.
The goal of the trial is to compare the efficacy and costs of bevacizumab 1.25 mg and ranibizumab 0.5mg given as monthly intravitreal injections over 6 months for the treatment of diabetic macular edema.
*To evaluate the safety and tolerability of RO7009789 and vanucizumab when administered in combination* To determine the maximum tolerated dose (MTD) (for the SC administration and potentially for the IV), route and recommended Phase II dose of…
Phase A:Primary objective: Determining the feasibility of gemcitabine as a radiosensitizer in DIPG Secondary objective: Evaluation of efficacy in terms of clinical and radiological response rate and progression free survivalTertiary objectives:…
The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular…
This study has 2 primary objectives:1) To determine the time point of induction of VEGF expression in the tumour tissue of oesophagus carcinomas during chemoradiation. 2) To determine whether the tumour promoting effects of this induction of VEGF…
Primary Efficacy ObjectivesUnless otherwise specified, efficacy objectives will be analyzed for the following two treatment comparisons:• Atezolizumab + carboplatin + paclitaxel + bevacizumab (Arm B) versus carboplatin + paclitaxel + bevacizumab (…
Primary objectiveTo assess the efficacy of the combination of osimertinib and bevacizumab versus osimertinib alone in terms of progression-free survival (PFS) assessed by RECIST 1.1.Secondary Objectives:To compare short and long term clinical…
Primary Objective* The primary objective of this study is to compare the confirmed objective response rate (ORR) by Week 19 following treatment with bevacizumab-Pfizer in combination with paclitaxel and carboplatin to bevacizumab-EU plus paclitaxel…